October 2019 Br J Cardiol 2019;26:145–8 doi :10.5837/bjc.2019.035
Protik Chaudhury, Min Aung, Rossella Barbagallo, Edward Barden, Swamy Gedela, Stuart J Harris, Henry O Savage, Jason N Dungu
Cardiac magnetic resonance (CMR) imaging has developed into a crucial diagnostic tool in all patients with known or suspected heart disease. The aim of this study was to review real-world data regarding the case mix and performance of stress CMR for the large Essex region, a population of 1.4 million.
All studies from April 2017 to April 2018 were reviewed. All scans were performed on a 1.5-T scanner (Siemens MAGNETOM Aera). We have not included research scans or repeat studies. A total of 1,706 clinical studies were performed, including 592 adenosine stress perfusion scans (35%). Mean age of patients was 59 years ± 16 (range 16–97) and the majority were male (66%). Ischaemic heart disease (IHD) was diagnosed in 28% of patients. Objective ischaemia was evident in 226 cases (38% of all stress scans). The positive predictive value of stress imaging was 91%. Non-ischaemic cardiomyopathies were diagnosed in 598 patients (35%), including dilated cardiomyopathy (DCM, 23%) and hypertrophic cardiomyopathy (HCM, 8%) as the most common phenotypes. The mean left ventricular ejection fraction (LVEF) was 51% across all groups (range 3–78%) with a significant difference between ischaemic and non-ischaemic cardiomyopathy (48% vs. 41%, p<0.0001); despite this, there was no significant difference in survival (p=0.177).
In conclusion, stress perfusion imaging accurately identifies true-positive ischaemia, as well as offering additional information regarding cardiac structure. The burden of non-ischaemic cardiomyopathy in Essex is significant, with 50 new diagnoses per month, across five hospitals. Coordination of services is needed to standardise practice and management of cardiomyopathy patients.
October 2019 Br J Cardiol 2019;26:137–40 doi :10.5837/bjc.2019.036
Harshal Deshmukh, Deepa Narayanan, Maria Papageorgiou, Yvonne Holloway, Sadaf Ali, Thozhukat Sathyapalan
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have opened a new avenue in the management of dyslipidaemia in patients with familial hypercholesterolaemia (FH), but real-world experience with PCSK9 inhibitors is limited.
We aimed to explore the efficacy and safety of PCSK9 inhibitors in a single-centre study, and to conduct a meta-analysis of the available observational studies to report pooled data on these efficacy and safety parameters.
The Hull PCSK9 inhibitor study consisted of patients from the Lipid Clinic at the Hull Royal Infirmary–Hull University Teaching Hospitals NHS Trust during the period 2016–2018. Patients with FH and atherosclerotic cardiovascular disease (ASCVD) were screened for eligibility and were prescribed PCSK9 inhibitors. Lipid profile, liver function, renal function, and creatine kinase levels were measured at baseline and after a 12-week follow-up. For the meta-analysis, review of the literature identified six additional observational studies for FH, which were used to calculate pooled percentage low-density lipoprotein (LDL)-cholesterol (LDL-C) reduction.
The Hull PCSK9 inhibitor study consisted of 16 patients with definite FH (LDL-receptor mutation-positive), 20 patients with clinical FH and 15 patients with ASCVD with a mean age of 60.6 ± 13.9 years, 60% female. Baseline median (interquartile range) LDL-C levels (mmol/L) in the definite FH, clinical FH and ASCVD were 4.9 (4.6–5.9), 6.7 (5.3–7.1) and 4.4 (4.1–4.7). After 12 weeks, the LDL-C levels (mmol/L) dropped significantly (p<0.0001) in all three groups to 2.0 (1.6–3.4), 2.3 (1.9–2.6) and 2.2 (1.7–2.8) in the definite FH, clinical FH and ASCVD groups, respectively. The meta-analysis of the seven observational studies in 446 patients with FH showed pooled mean reduction of 55.5 ± 18.1% in the LDL-C levels, with 58% of patients reaching treatment targets. Treatment-associated side effects occurred in 6% to 45% of patients, and 0–15% of patients discontinued treatment due to intolerable side effects.
In conclusion, we showed that PCSK9 inhibitors are overall well-tolerated when used in real-world settings, and their efficacy is comparable with that reported in clinical trials. Longitudinal population-based registries are needed to monitor responses to treatment, treatment adherence and side effects of these lipid-lowering agents.
October 2019 Br J Cardiol 2019;26:159–60 doi :10.5837/bjc.2019.037
Matthew J Johnson, Rohan Penmetcha
Cardiac tamponade and myocardial infarction (MI) are rare as the initial presentation of a malignancy. ST-elevation myocardial infarction (STEMI) and cardiac tamponade have been described to present together in the setting of a type-A aortic dissection causing coronary malperfusion. We describe a case with an atypical presentation of an MI due to a thrombus in the right coronary artery occurring simultaneously with a pericardial effusion causing tamponade physiology, related to malignancy. We present this unique case of MI and cardiac tamponade as it was not caused by a type-A aortic dissection. We suggest that malignancy be considered in the differential diagnosis when these findings present together.
September 2019 Br J Cardiol 2019;26:99–100 doi :10.5837/bjc.2019.028
Anthony P C Bacon, Harry Rosen, Neil Ruparelia
The management of aortic stenosis has dramatically changed over the last 60 years. We briefly describe these remarkable advances from the personal perspective of Anthony P C Bacon (APCB) who was one of the first physicians to observe the importance of this pathological process and who watched, first-hand, some of the first surgical aortic valve procedures being performed in the UK. He most recently benefited from treatment with transcatheter aortic valve implantation (TAVI) himself, and provides a personal perspective of his experiences.
September 2019 Br J Cardiol 2019;26:105–9 doi :10.5837/bjc.2019.029
Paul Brady, Andrew Kelion, Tom Hyde, Edward Barnes, Hazim Rahbi, Andy Beale, Steve Ramcharitar
In November 2016, the National Institute for Health and Care Excellence (NICE) published an update of its guideline for the investigation of chest pain of recent onset (CG95), bringing computed tomography coronary angiography (CTCA) to the forefront as the first-line investigation. CTCA has a high negative-predictive value for the identification of obstructive coronary artery disease (CAD), but its positive-predictive value may be as low as 48%. Moreover, until recently it was unable to determine the functional significance of stenoses identified by CTCA. Using advanced computational fluid dynamics (CFD), HeartFlow® has pioneered a system that can predict the invasive fractional flow reserve (FFR) from a standard CTCA acquisition (FFRCT). The PLATFORM study has demonstrated that the use of CTCA with FFRCT was associated with equivalent clinical outcomes in terms of major adverse cardiovascular events (MACE) and quality of life at one year compared with usual testing. The global ADVANCE registry, and other long-term follow-up studies in over 9,000 patients, have demonstrated extremely good long-term outcomes when patients with CAD but negative FFRCT are managed conservatively without invasive testing. In a technology appraisal (MTG32), NICE projected that the adoption of this technology within the NHS in England could save at least £9.1 million by 2022. While it is accepted that the HeartFlow® FFRCT shows a lot of promise, there are a number of limitations that need to be considered.
September 2019 Br J Cardiol 2019;26:114–8 doi :10.5837/bjc.2019.030
Amir Orlev, Amna Abdel-Gadir, Graeme Tait, Jonathan P Bestwick, David S Wald
Radial artery access coronary angiography is associated with high procedural success and lower rates of complications, compared with femoral access, in patients without prior coronary artery bypass surgery (CABG). Whether or not this applies to patients who have undergone CABG is not known.
We retrospectively examined hospital records of 5,993 consecutive patients undergoing coronary angiography to identify patients with previous CABG undergoing the procedure by the radial or femoral access routes. We compared clinical characteristics, procedural success and complications up to 30 days, adjusting for significant baseline differences.
Among the 5,993 patients undergoing angiography, 471 (8%) had previous CABG; 164 (35%) underwent angiography by the radial and 307 (65%) by the femoral artery. Procedural success was lower in the radial than femoral groups; 28/164 (17%) radial versus 1/307 (0.3%) femoral patients required access-site cross-over (p<0.001) and 254/347 (73%) versus 496/594 (84%) bypass grafts were selectively identified without the need for further imaging investigations (p=0.008), respectively. Access-site bleeding requiring compression affected 1/164 (0.6%) in the radial group and 12/307 (3.9%) in the femoral group (p=0.04 for difference) with no significant differences in other major complications.
About one in 12 patients undergoing coronary angiography have had previous CABG surgery. In such patients, the radial access route was associated with lower procedural success than the femoral route but also a lower rate of bleeding complications.
September 2019 Br J Cardiol 2019;26:119 doi :10.5837/bjc.2019.031
Nicolas Buttinger, Mark Forde, Timothy Williams, Sally Curtis, James Cockburn
We describe a case of primary meningococcal Y effusive pericarditis in a previously fit and well 35-year-old man who presented with a rapidly developing pericardial effusion resulting in cardiac tamponade. This is a rare, but important, cause of primary pericardial disease, and only the fourth documented case of primary meningococcal pericarditis due to Neisseria meningitidis serotype Y. Our patient was successfully treated with a pericardial drain and intravenous ceftriaxone. Our case highlights the importance of adverse clinical features such as temperature >38°C, subacute course, large effusion or tamponade, and non-steroidal anti-inflammatory drug (NSAID)/aspirin failure, which can identify patients who require close observation as they are at higher risk of complications.
July 2019 Br J Cardiol 2019;26:110–3 doi :10.5837/bjc.2019.024
Matthew E Li Kam Wa, Pitt O Lim
Angiography of internal mammary artery (IMA) grafts continues to be a common indication for upfront femoral access. This is particularly the case for bilateral pedicled IMAs, or when the left radial artery has been grafted. While the right radial artery is ideally suited in these situations for cannulation of the right IMA, accessing the left IMA (LIMA) by this route is often perceived as challenging and for ‘radial evangelists’ only. We describe a case series showing a simple technique for selective cannulation of the LIMA from the right radial artery using a single catheter that provides sufficient backup for percutaneous coronary intervention (PCI).
July 2019 Br J Cardiol 2019;26:101–4 doi :10.5837/bjc.2019.025
Jeremy S Nayagam, Viral A Sagar, Maxwell Asante
Gastrointestinal (GI) symptoms are common in patients with postural orthostatic tachycardia syndrome (PoTS). Our understanding of managing GI symptoms in PoTS is very limited. Our objectives were to evaluate common GI symptoms, diagnostic work-up, diagnosis and management strategy in patients with PoTS.
We retrospectively reviewed medical records of all patients referred to the gastroenterology clinic (2014 to 2017) with GI symptoms and known or suspected PoTS: 85 patients with PoTS and GI symptoms were seen in our clinic. Bloating (75%), constipation (74%) and abdominal pain (60%) were the most common GI symptoms. Endoscopy, high-resolution manometry, gastric-emptying studies and colonic-transit studies were commonly performed investigations. Over two-thirds of patients had confirmed or suspected GI dysmotility, 5.9% had organic GI disease (e.g. inflammatory and acid peptic disorders).
In conclusion, the majority of patients with PoTS have a functional disturbance and reduced GI motility, however, a small proportion have organic disease that needs systematic evaluation. Dietary modifications and laxatives are the main modalities of therapy.
July 2019 Br J Cardiol 2019;26:92–6 doi :10.5837/bjc.2019.026
Subodh R Devabhaktuni, Ali O Malik, Ji Won Yoo, Xibei Liu, Vipul Shah, Syed I Shah, John M Ham, Bejon T Maneckshana, Jimmy Diep, Chowdhury H Ahsan
False-negative results either from balanced ischaemia or from failure to induce optimal hyperaemia is a known limitation of vasodilator myocardial perfusion imaging (MPI). We sought to identify the prevalence of false-negative results in the kidney transplant population and to identify the risk factors predictive of false-negative MPI results at our institution.
We retrospectively studied 133 consecutive patients who were referred to us for pre-operative evaluation. Mean age was 56 years and 70% of the subjects were males. All patients who underwent vasodilator MPI and computed tomography coronary angiography (CTCA) were included.
In the studied population, false-negative vasodilator MPI test result prevalence was around 13%. In uni-variable and multi-variable analysis, diabetes and cardiovascular disease (CVD) were predictive of false-negative vasodilator MPI testing results. CTCA had a positive-predictive value (PPV) of 82%.
In conclusion, false-negative results, either from balanced ischaemia or from failure to induce optimal hyperaemia, are a major problem in the pre-operative evaluation of renal transplant patients when the vasodilator MPI test is used. CTCA could be a useful imaging modality in this patient population. We found that diabetes and CVD are significantly associated with false-negative MPI results.